REFERENCES
1. Swerdloff RS, Ng JCM. Gynecomastia: etiology, diagnosis, and treatment. Endotext [Internet]. 2023;
2. (GAEI) GA para el E de las EI, Mira JA, Lozano F, Santos J, Ramayo E, Terrón A, et al. Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment. Antivir Ther. 2004;9(4):511–7.
3. Biglia A, Blanco JL, Martínez E, Domingo P, Casamitjana R, Sambeat M, et al. Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study. Clin Infect Dis. 2004;39(10):1514–9.
4. Kanakis GA, Nordkap L, Bang AK, Calogero AE, Bártfai G, Corona G, et al. EAA clinical practice guidelines—gynecomastia evaluation and management. Andrology. 2019;7(6):778–93.
5. Catherine B. Niewoehner, Dennis Styne, Harold Carlson and GB. Gynecomastia. BMJ Best Pract [Internet]. 2022; Available from: https://bestpractice.bmj.com/topics/en-gb/869
6. Liverpool HIV Drug Interactions Checker. Liverpool HIV Drug Interactions Checker. [Internet]. Available from: https://www.hiv-druginteractions.org/checker
7. Notts APC. Gynaecomastia in Adults Guideline. https://www.nottsapc.nhs.uk/media/1519/gynaecomastia-guideline.pdf [Internet]. 2023; Available from: https://www.nottsapc.nhs.uk/media/1519/gynaecomastia-guideline.pdf
8. Hodge D, Back DJ, Gibbons S, Khoo SH, Marzolini C. Pharmacokinetics and drug–drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin Pharmacokinet. 2021;60:835–53.
9. Kegg S, Lau R. Tamoxifen in antiretroviral-associated gynaecomastia. Int J STD AIDS. 2002;13(8):582–3.
10. Parker LN, Gray DR, Lai MK, Levin ER. Treatment of gynecomastia with tamoxifen: a double-blind crossover study. Metabolism. 1986;35(8):705–8.
11. Association of Breast Surgery. Summary statement on the investigation and management of gynaecomastia in primary & secondary care. 2019; Available from: https://associationofbreastsurgery.org.uk/media/334385/breast-surgery-v7.pdf
12. Grimm SW, Dyroff MC. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos. 1997;25(5):598–602.
13. Robertson JFR, Paridaens RJ, Lichfield J, Bradbury I, Campbell C. Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer. Eur J Cancer. 2021;145:19–28.
14. Hyder T, Marino CC, Ahmad S, Nasrazadani A, Brufsky AM. Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management. Front Endocrinol (Lausanne). 2021;12:713700.
15. Liu M, Goss PE, Ingle JN, Kubo M, Furukawa Y, Batzler A, et al. Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. Mol Endocrinol. 2014;28(10):1740–51.
16. Korani M. Aromatase inhibitors in male: A literature review. Med Clin Pract [Internet]. 2023;6(1):100356. Available from: https://doi.org/10.1016/j.mcpsp.2022.100356
17. Plourde P V, Reiter EO, Jou H-C, Desrochers PE, Rubin SD, Bercu BB, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89(9):4428–33.